11:36 AM
 | 
Jan 19, 2018
 |  BC Week In Review  |  Clinical News  |  Regulatory

Albireo gets $55M for elobixibat approval in Japan

Albireo Pharma Inc. (NASDAQ:ALBO) nearly doubled its cash reserves after Japan’s Ministry of Health, Labour and Welfare (MHLW) approved Goofice elobixibat to treat chronic constipation. The approval triggered about $55 million in payments to the company's Elobix AB subsidiary from HealthCare Royalty Partners (Stamford, Conn.) and the EA Pharma Co. Ltd. subsidiary of...

Read the full 243 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >